Skip to main content
    P

    Plus Therapeutics Inc (PSTV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    +0.18 (+23.32%)

    Market Cap: $26.64M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Plus Therapeutics Inc (PSTV) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2026. Financial statements from company filings, amounts in US dollars.

    Plus Therapeutics reported revenue of $5.21M for the fiscal year ended Dec 31, 2025, down 10.5% from the year before. That year, net income was -$22.39M with a net margin of -429.4%, operating cash flow was -$20.77M and free cash flow was -$20.84M. The quarter ended Sep 30, 2026 had revenue of $722.00K and net income of -$8.66M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $4.66M, a compound annual rate of 1.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$5.21M-10.5%100.0%-293.5%-429.4%
    Dec 2024$5.82M+18.5%100.0%-252.3%-222.8%
    Dec 2023$4.91M+2093.3%100.0%-271.1%-271.0%
    Dec 2022$224.00KN/A100.0%-8800.0%-9051.3%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0-100.0%N/AN/AN/A
    Dec 2017$2.69M-42.2%5.4%-769.2%-843.7%
    Dec 2016$4.66MN/A41.7%-423.2%-473.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$5.21M$5.82M$4.91M$224.00K$0$0$0$0$2.69M$4.66M
    Cost of revenue$0$0$0$0$0$0$0$0$2.54M$2.71M
    Gross profit$5.21M$5.82M$4.91M$224.00K$0$0$0$0$146.00K$1.94M
    Research and development$8.38M$10.58M$9.69M$9.70M$5.57M$3.48M$5.37M$5.52M$13.36M$9.47M
    Operating income-$15.30M-$14.70M-$13.32M-$19.71M-$12.49M-$9.58M-$3.66M-$8.76M-$20.68M-$19.71M
    Net income-$22.39M-$12.98M-$13.32M-$20.27M-$13.40M-$8.24M-$10.89M-$12.63M-$22.69M-$22.05M
    EBITDAN/A-$12.31M-$12.50M-$18.70M-$11.52M-$6.23M-$2.21M-$3.95M-$17.81M-$17.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$722.00K$411.00K$1.03M$1.37M$1.40M$1.39M$1.06M$1.41M$1.46M$1.28M$1.68M$1.31M
    Gross profit$722.00K$411.00K$1.03M$1.37M$1.40M$1.39M$1.06M$1.41M$1.46M$1.28M$1.68M$1.31M
    Operating income-$7.46M-$9.06M-$7.12M-$5.74M-$4.48M-$1.54M-$3.54M-$3.90M-$3.80M-$3.70M-$3.30M-$3.86M
    Net income-$8.66M-$9.01M-$6.95M-$5.71M-$4.42M$5.15M-$17.40M-$3.90M-$2.87M-$2.94M-$3.26M-$3.81M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $750.00K by $3.51M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$16.32M$6.63M$11.39M$23.87M$21.98M$12.11M$23.23M$23.99M$31.61M$34.61M
    Current assets$14.85M$5.26M$9.83M$21.82M$19.72M$9.18M$19.82M$9.65M$14.86M$18.75M
    Cash and equivalents$4.26M$76.00K$8.55M$18.12M$18.40M$8.35M$17.55M$5.26M$9.55M$12.56M
    Total liabilities$12.33M$15.58M$12.74M$17.42M$11.14M$9.07M$22.07M$18.77M$18.61M$23.62M
    Short-term debt$750.00K$3.29M$3.98M$1.61M$1.61M$6.33M$11.06M$14.20M$13.62M$6.63M
    Long-term debtN/AN/AN/A$3.79M$5.00MN/AN/A$0$0$11.01M
    Shareholder equity$4.00M-$8.95M-$1.35M$6.45M$10.84M$3.03M$1.16M$5.22M$13.00M$10.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$12.20M$14.03M$19.92M$16.32M$18.67M$10.35M$12.06M$6.63M$6.98M$11.21M$5.62M$11.39M
    Total liabilities$13.12M$8.57M$7.96M$12.33M$13.62M$7.32M$35.70M$15.58M$12.15M$18.84M$10.46M$12.74M
    Cash and equivalents$879.00K$2.37M$3.02M$8.76M$13.29M$2.23M$9.87M$76.00K$1.22M$4.91M$2.90M$8.55M
    Shareholder equity-$923.00K$5.46M$11.96M$4.00M$5.05M$3.03M-$23.64M-$8.95M-$5.17M-$7.63M-$4.84M-$1.35M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$20.77M-$10.55M-$12.85M-$12.97M-$10.28M-$8.43M-$5.91M-$11.97M-$18.13M-$19.53M
    Capital expenditures$67.00K$146.00K$160.00K$509.00K$144.00K$93.00K$67.00K$133.00K$1.50M$67.00K
    Free cash flow-$20.84M-$10.70M-$13.01M-$13.48M-$10.42M-$8.53M-$5.97M-$12.11M-$19.62M-$19.60M
    Dividends paidN/AN/A$348.00KN/AN/AN/AN/A$0$2.08M$75.00K
    Share repurchases$231.00K$374.00K$474.00K$773.00K$0N/A$0N/A$2.08M$2.08M
    Investing cash flow-$854.00K-$4.11M-$160.00K-$759.00K-$82.00K-$493.00K$5.57M-$133.00K-$1.38M$64.00K
    Financing cash flow$30.31M$6.19M$3.44M$13.45M$20.42M-$319.00K$12.63M$7.17M$16.82M$17.61M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$7.67M-$7.13M-$6.24M-$6.26M-$2.55M-$5.80M-$6.17M-$1.21M-$3.68M-$1.15M-$4.51M-$1.88M
    Capital expenditures$51.00K$499.00K$818.00K$30.00K$27.00K$7.00K$3.00K$11.00K$14.00K$81.00K$40.00K$42.00K
    Free cash flow-$7.72M-$7.63M-$7.06M-$6.29M-$2.58M-$5.80M-$6.17M-$1.22M-$3.69M-$1.23M-$4.55M-$1.92M
    Last 12 quarters

    Frequently Asked Questions About PSTV

    What is Plus Therapeutics' annual revenue?

    Plus Therapeutics reported revenue of $5.21M for the fiscal year ended Dec 31, 2025.

    How fast is Plus Therapeutics' revenue growing?

    Revenue was down 10.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 185.5%.

    Is Plus Therapeutics profitable?

    No. Plus Therapeutics reported net income of -$22.39M for the fiscal year ended Dec 31, 2025, with a net margin of -429.4%.

    How much free cash flow does PSTV generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$20.77M minus capital expenditures of $67.00K produced free cash flow of -$20.84M.

    How much debt does Plus Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $750.00K and cash and equivalents of $4.26M.